Nyxoah SA（NYXH）資訊與事件NYXHNyxoah SA

Nyxoah Reports Over 20% Sequential U.S. Revenue Growth in Q2

"We closed Q2 with clear U.S. momentum: the scaling of our U.S. sales force allowed us to double the number of active accounts to 180 high-volume HGNS accounts and deliver a second consecutive quarter of over 20% sequential U.S. revenue growth. Additionally, the recent CMS proposed reimbursement increases in both hospital outpatient and ambulatory surgical centers are among the strongest within APC 5465 and, if approved, support continued economic value for the Genio procedure," commented Olivier Taelman, Nyxoah's CEO. "With $110 million in new financing, the financial overhang is now behind us, and we are positioned to accelerate Genio's U.S. commercial ramp and drive toward profitability."

Company Expects 2026 Global Net Revenue of EUR 36M to EUR 40M

The company said, "The Company continues to expect global net revenue for the full year 2026 to be in the range of EUR 36 million to EUR 40 million."

Nyxoah Plans to Close Offering Around June 9

The offering is expected to close on or around June 9, subject to the satisfaction of customary closing conditions. Nyxoah intends to use the net proceeds from the offering (i) for expanding commercialization activities in the United States; (ii) to further finance research and development activities related to Genio system upgrades, re-designing its products for manufacturability and cost reduction initiatives, and to continue to build a pipeline of new technologies and explore potential collaboration opportunities in the field of monitoring and diagnostics for OSA; (iii) to advance commercialization of the Genio system in its initial target markets outside of the United States and to continue gathering clinical data and to support physician initiated clinical research projects related to OSA patient treatments; and (iv) for other general corporate purposes, including, but not limited to, working capital, repayment of debt financing, capital expenditures, investments, acquisitions, should the Company choose to pursue any, and collaborations. BofA acted as lead book running manager for the offering.